Pharmaceutical

‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033

Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.

Jun 7, 2025 - 06:00
‘Dupixent-fuelled’ atopic dermatitis market sales to hit $22.4bn by 2033
Regeneron and Sanofi’s blockbuster Dupixent has transformed the atopic dermatitis market, with future disruptors in the pipeline.
Read the original article

Tags:

Previous Article

EC authorises Sydnexis’ paediatric myopia treatment

Next Article

Bayer subsidiary Vividion secures rights to Werner helicase inhibitor

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Sage considers ways to reduce costs following FDA rejection on drug for major depression

STAT+: Sage considers ways to reduce costs following FD...

Aug 7, 2023

test

Apr 16, 2023

Opinion: BMI as a barrier to orthopedic surgery doesn’t make sense for patient health

Opinion: BMI as a barrier to orthopedic surgery doesn’t...

Jan 16, 2024